Repligen Corporation (FRA:RGN)
Germany · Delayed Price · Currency is EUR | Market Cap | 6.50B +16.0% |
| Revenue (ttm) | 662.04M +17.4% |
| Net Income | 44.58M |
| EPS | 0.79 |
| Shares Out | n/a |
| PE Ratio | 145.87 |
| Forward PE | 58.58 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 113.75 |
| Previous Close | 115.10 |
| Day's Range | 113.75 - 113.75 |
| 52-Week Range | 86.32 - 147.10 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 28, 2026 |
About Repligen
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company’s products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spect... [Read more]
News
Repligen Earnings Call Transcript: Q2 2026
Q2 2026 saw 13% organic revenue growth, margin expansion, and strong performance in proteins and analytics. Full-year guidance was raised for revenue and EPS, with BioLife acquisition set to accelerate cell therapy growth and deliver financial synergies.
Repligen Earnings release: Q2 2026
Repligen released its Q2 2026 earnings on July 28, 2026, summarizing the period's financial results.
Repligen Slides: Q2 2026
Repligen has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 28, 2026.
Repligen reports Q2 adjusted EPS 54c, consensus 45c
Reports Q2 revenue $204.13M, consensus $201.4M. Olivier Loeillot, President and Chief Executive Officer of Repligen (RGEN) said, “We were very pleased to deliver 13% organic growth in the second quart...
Repligen raises FY26 EPS view to $2.03-$2.09 from $1.97-$2.05, consensus $2.00
Raises FY26 revenue view to $813M-$835M from $803M-$833M, consensus $821.04M. The company said, “Our financial guidance for the full year 2026 is based on expectations for our existing business. Our…
Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
WALTHAM, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its s...
BioLife Solutions to be acquired by Repligen in $1.5B cell therapy deal
BioLife Solutions, a Bothell, Wash.-based company developing tools for cell and gene therapy, is being acquired for $1.5 billion by the life sciences corporation Repligen.
BioLife Solutions downgraded to Hold from Buy at Lake Street
Lake Street downgraded BioLife Solutions (BLFS) to Hold from Buy with a price target of $31, down from $33, after Repligen (RGEN) announced a definitive agreement to acquire the company…
Repligen Transcript: M&A announcement
The $1.5 billion acquisition of BioLife Solutions accelerates leadership in cell therapy, adds a highly complementary portfolio, and is expected to be accretive to growth, margins, and EPS from year one. Integration is planned over 12–24 months, with at least $20 million in year one synergies and significant cross-selling opportunities, especially in Asia.
Repligen Press release: M&A announcement
Repligen issued a press release on July 22, 2026, disclosing material business information to investors.
Repligen Slides: M&A announcement
Repligen has posted slides in relation to its latest quarterly earnings report, which was published on July 22, 2026.
Repligen to buy cell therapy maker BioLife in $1.5 billion deal
Repligen Corp said on Wednesday it would buy BioLife Solutions in a cash-and-stock deal valued at about $1.5 billion, to expand the drugmaking equipment provider's presence in the fast-growing ce...
Repligen to acquire BioLife Solutions for $31 per share, or $1.5B
06:01 EDT Repligen (RGEN) to acquire BioLife Solutions (BLFS) for $31 per share, or $1.5B
Repligen to acquire BioLife Solutions for $31 per share, or $1.5B
Repligen (RGEN) and BioLife Solutions (BLFS) announced they have entered into a definitive agreement under which Repligen, subject to customary closing conditions, will acquire BioLife for a total ent...
Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation Media
Fast-tracks Repligen's leadership and customer solution offering in high-growth cell therapy market by adding BioLife's differentiated, high-margin recurring revenue business
Repligen to Report Second Quarter 2026 Financial Results
Webcast and Conference Call to Be Held Tuesday, July 28, 2026, at 8:00 a.m. ET Webcast and Conference Call to Be Held Tuesday, July 28, 2026, at 8:00 a.m. ET
Repligen upgraded to Buy from Hold at Benchmark
Benchmark analyst Robert Wasserman upgraded Repligen (RGEN) to Buy from Hold with an $185 price target citing improved quarterly financial performance as well as increased valuations for comparable bi...
Repligen price target raised to $160 from $150 at Evercore ISI
Evercore ISI raised the firm’s price target on Repligen (RGEN) to $160 from $150 and keeps an Outperform rating on the shares. The firm’s Q2 preview for MedTech, Life Sciences…
Biolife attracts takeover interest from Repligen, Bloomberg says
Biolife Solutions (BLFS) has drawn takeover interest from several parties, including Repligen (RGEN), Bloomberg’s Dinesh Nair and Michelle F. Davis report, citing people with knowledge of the matter. ...
Repligen Transcript: 46th Annual William Blair Growth Stock Conference
Innovation and diversification are fueling strong growth, with a focus on expanding in Asia, accelerating digital transformation, and improving operational efficiency. Despite headwinds, analytics and chromatography are driving robust performance, and the company is confident in meeting its financial guidance.
Repligen Slides: 46th Annual William Blair Growth Stock Conference
Repligen has posted slides in relation to its latest quarterly earnings report, which was published on June 3, 2026.
Repligen price target lowered to $150 from $170 at HSBC
HSBC lowered the firm’s price target on Repligen (RGEN) to $150 from $170 and keeps a Buy rating on the shares. The firm says market expectations on life science tools…
Repligen assumed with an Outperform at Wolfe Research
Wolfe Research assumed coverage of Repligen (RGEN) with an Outperform rating and $145 price target The company is a bioprocessing pure play with highly differentiated products in sub-segments like ups...